Literature DB >> 32631779

Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma.

Nitya Nathwani1, Joycelynne Palmer2, Timothy W Synold3, Behrouz Salehian4, Michael Rosenzweig5, James F Sanchez5, Samantha N Hammond6, Kehinde Adekola7, Valeria Tomarchio5, Arnab Chowdhury5, Chatchada Karanes5, Myo Htut5, Firoozeh Sahebi8, Tanya Siddiqi9, Amrita Krishnan5, Stephen J Forman9, Steven T Rosen9.   

Abstract

Entities:  

Keywords:  Adverse events; Glucose transporters; Hematologic malignancies; Nelfinavir; Protease inhibitors

Year:  2020        PMID： 32631779      PMCID： PMC7541704          DOI： 10.1016/j.clml.2020.05.017

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


× No keyword cloud information.
  48 in total

1.  Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers.

Authors:  J Alsenz; H Steffen; R Alex
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

Review 2.  Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects.

Authors:  Arian Emami Riedmaier; Pascale Fisel; Anne T Nies; Elke Schaeffeler; Matthias Schwab
Journal:  Trends Pharmacol Sci       Date:  2012-12-29       Impact factor: 14.819

3.  Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

Authors:  S K Kumar; J H Lee; J J Lahuerta; G Morgan; P G Richardson; J Crowley; J Haessler; J Feather; A Hoering; P Moreau; X LeLeu; C Hulin; S K Klein; P Sonneveld; D Siegel; J Bladé; H Goldschmidt; S Jagannath; J S Miguel; R Orlowski; A Palumbo; O Sezer; S V Rajkumar; B G M Durie
Journal:  Leukemia       Date:  2011-07-29       Impact factor: 11.528

4.  Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer.

Authors:  Anjaiah Srirangam; Ranjana Mitra; Mu Wang; J Christopher Gorski; Sunil Badve; LeeAnn Baldridge; Justin Hamilton; Hiromitsu Kishimoto; John Hawes; Lang Li; Christie M Orschell; Edward F Srour; Janice S Blum; David Donner; George W Sledge; Harikrishna Nakshatri; David A Potter
Journal:  Clin Cancer Res       Date:  2006-03-15       Impact factor: 12.531

5.  Lactic acidosis in HIV patients receiving highly active antiretroviral therapy.

Authors:  Y W Chow; C L Leong; H L Chow; L S Hooi
Journal:  Med J Malaysia       Date:  2007-03

6.  Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metformin.

Authors:  Kehinde U A Adekola; Sevim Dalva Aydemir; Shuo Ma; Zheng Zhou; Steven T Rosen; Mala Shanmugam
Journal:  Leuk Lymphoma       Date:  2014-08-04

Review 7.  Biguanide-associated lactic acidosis. Case report and review of the literature.

Authors:  S C Gan; J Barr; A I Arieff; R G Pearl
Journal:  Arch Intern Med       Date:  1992-11

8.  The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma.

Authors:  W Wu; K Merriman; A Nabaah; N Seval; D Seval; H Lin; M Wang; M H Qazilbash; V Baladandayuthapani; D Berry; R Z Orlowski; M-H Lee; S-C J Yeung
Journal:  Br J Cancer       Date:  2014-06-12       Impact factor: 7.640

9.  Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms.

Authors:  Samuel K McBrayer; Michael Yarrington; Jun Qian; Gang Feng; Mala Shanmugam; Varsha Gandhi; Nancy L Krett; Steven T Rosen
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

Review 10.  The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies.

Authors:  Akinori Sato
Journal:  Onco Targets Ther       Date:  2015-04-08       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.